| 陈军 宁平 刘泽宇 雷蕾 盛涛.乳腺癌患者加用重组人粒细胞集落刺激因子骨髓支持治疗的效果探讨[J].,2015,15(26):5119-5121 |
| 乳腺癌患者加用重组人粒细胞集落刺激因子骨髓支持治疗的效果探讨 |
| Effect of Recombinant Human Granulocyte-Colony Stimulating FactorSupport Treatment in Breast Cancer |
| |
| DOI： |
| 中文关键词: 乳腺癌 重组人粒细胞集落刺激因子 骨髓毒性反应 |
| 英文关键词: Breast cancer Recombinant human granulocyte-colony stimulating factor Bone marrow toxicity |
| 基金项目: |
|
| 摘要点击次数: 650 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨乳腺癌患者加用重组人粒细胞集落刺激因子（rhG-CSF）骨髓支持治疗的临床效果。方法：将我院2011 年1 月
-2012 年12 月收治的106例乳腺癌患者随机分为对照组及观察组，每组53 例。两组均给予常规化疗治疗，观察组在此基础上加
用rhG-CSF骨髓支持治疗，比较两组治疗前后血象变化及骨髓毒性反应情况。结果：对照组治疗后WBC、ANC、Plt 及Hb 与治疗
前比较均有显著降低，且差异具有统计学意义（P<0.05）；而观察组治疗后以上血象指标较治疗前变化不明显（P>0.05），但与对照
组同期比较具有显著性差异（P<0.05）；观察组骨髓毒性反应较对照组轻，Ⅱ度以上发生率为26.42%，显著低于对照组的47.17%
（P<0.05）。结论：乳腺癌患者加用rhG-CSF骨髓支持治疗可明显缓解患者化疗后的骨髓抑制反应，减少其骨髓毒性反应发生，对
化疗导致白细胞数减少具有较好的预防和临床应用价值，值得进一步推广和应用。 |
| 英文摘要: |
| Objective:To investigate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) support
treatment in breast cancer.Methods:A total of 106 patients with breast cancer, who were admitted to Chengdu Center Hospital forWomen
and Children from January 2011 to December 2012, were randomly divided into observation group (n=53) and control group(n=53).
The two groups were given conventional chemotherapy, while support treatment with rhG-CSF was added to the observation group. The
hemogram change and bone marrow toxicity of two groups before and after treatment were compared.Results:Compared with before
treatment, the WBC, ANC, Plt and Hb of control group after treatment significantly decreased,the differences were statistically significant
(P<0.05); while the above-mentioned hemogramindexes of observation group after treatment little changed (P>0.05), but compared with
the control group, the differences were statistically significant (P<0.05). Bone marrow toxicities of observation group was lower than
those of control group, and the incidence of grade Ⅱ or above in observation group was 26.42%, significantly lower than that (47.17%)
of control group (P<0.05).Conclusion:Adding rhG-CSF support treatment to the patients with breast cancer can obviously relieve the incidence
of bone marrow toxicities and prevent the number of white blood cells from reducing, caused by chemotherapy, which is worthy
of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
